Heron Therapeutics Inc vs Upstart Holdings Inc — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Upstart Holdings Inc trades at $23.9 (market cap $2.35B). The key difference: Upstart Holdings Inc is far larger — about 34.6× Heron Therapeutics Inc's market cap, and Upstart Holdings Inc is more actively traded (4,203,337 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Upstart Holdings Inc for 39 Days on average.
| HRTX | UPST | |
|---|---|---|
Market Cap | $68.01M | $2.35B |
Volume | 1,891,941 | 4,203,337 |
Sector | Health | Financials |
52-Week High | $1.49 | $52.74 |
52-Week Low | $0.27 | $22.81 |
Typical Hold Time | 35 Days | 39 Days |
Enterprise Value | $174.75M | $3.88B |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Upstart Holdings (UPST) trades at $24.02, up 0.67% with mixed technical signals showing bearish momentum but neutral oscillators. The company reported revenue growth to $1.02B in 2025 with a return to profitability ($53.6M net income), though recent quarters show earnings misses. Analyst sentiment is divided with a $39.50 consensus target, while recent news highlights partnership expansions and sector volatility affecting consumer lending stocks.
The outlook balances AI-driven lending growth against credit market risks and earnings volatility. Investment opportunity lies in valuation upside if execution improves, but risks include debt levels rising to 61.48% of assets and consistent earnings underperformance. The stock's proximity to recent lows suggests cautious investor sentiment amid sector headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →